论文部分内容阅读
目的探讨第三肝门成形术[经皮腔内血管成形术(PTA)及支架置入术]在BuddChiari综合征(BCS)介入治疗中的临床应用价值。方法本组20例BCS患者,其中男12例,女8例,年龄17~53岁,采用直接或标识下经股静脉或颈静脉第三肝门成形术,或采用Rendezvous技术第三肝门成形术。结果全部病例实施第三肝门靶血管PTA及支架置入术,均获得成功,未出现严重并发症。单纯PTA治疗12例,支架置入术8例(共置入支架9个)。术后随访3~54个月,临床治愈10例,有效7例,无效3例。有效率为85%。结论第三肝门成形术作为治疗肝静脉型BCS是一种安全、有效的新方法,有着与第二肝门成形术同等的治疗价值。
Objective To investigate the clinical value of the third hilar angioplasty (percutaneous transluminal angioplasty (PTA) and stenting] in the interventional treatment of Budd-Chiari syndrome (BCS). Methods The group of 20 patients with BCS, including 12 males and 8 females, aged 17 to 53 years, with direct or identified by the femoral vein or jugular vein in the third hilar or Rendezvous the third hilar formation Surgery. Results All the patients underwent the third hepatic target vessel PTA and stenting, which were successful without serious complications. Simple PTA treatment in 12 cases, stent implantation in 8 cases (a total of 9 stent placement). The patients were followed up for 3 to 54 months. There were 10 cases clinically cured, 7 effective and 3 ineffective. The effective rate is 85%. Conclusion The third hilar angioplasty as a treatment of hepatic vein BCS is a safe and effective new method, and has the same value as the second hilar angioplasty.